Terbinafine Tablet
Product Images NDC 70518-4421

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Terbinafine (NDC 70518-4421). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This is a description of Terbinafine tablets, each containing 250 mg, with a quantity of 90 tablets. The tablets are white and round. The usual dosage is mentioned in the insert. The tablets are repackaged by RemedyRepack Inc. in Indiana, PA. The original NDC number is 69097-0859-07, and the tablets are manufactured by Cipla Ltd in India. It is advised to keep the medication away from children and store it at a temperature range of 20-25°C (68-77°F), with excursions permitted to 15-30°C (59-86°F) as per USP standards.*

FDA Label Image

Mm2 (Terbinafine 250mg 70518 4421 01)

Description: Terbinafine Tablets, 250 mg, quantity of 45 tablets. The tablets are round and white. The package is repackaged by RemedyRepack Inc. with NDC number 70518-4421-01. The tablets are manufactured by Cipla Ltd in Kurkumnbh, India. The usual dosage information can be found in the insert included. It is important to store the medication at 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F). Remember to keep the medication out of the reach of children.*

FDA Label Image

Image 2 (Terbinafine Str)

FDA Label Image

Image 1 (Terbinafine Table)

This is a table displaying adverse events and discontinuation rates for patients taking Terbinafine Tablets compared to Placebo. Adverse events such as headache, gastrointestinal symptoms (e.g., diarrhea, dyspepsia, abdominal pain, nausea, flatulence), dermatological symptoms (e.g., rash, pruritus, urticaria), liver enzyme abnormalities, taste disturbance, and visual disturbance are listed along with the percentages of patients experiencing them in each group.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.